Blepharitis Treatment Market Revenue Opportunies By Key Vendors Scope Ophthalmic Ltd, NovaBay Pharmaceuticals Inc, Thea Pharmaceuticals Ltd, Perrigo Laboratories, InSite and Novartis AG

The blepharitis treatment market is expected to witness significant grow due to growing prevalence of ophthalmic disorders among the geriatric population. According to a survey conducted by American Academy of Ophthalmology in 2014, blepharitis usually affects people above the age of 50 years. It also states that blepharitis is observed in 37% male ophthalmic patients and 47% in female ophthalmic patients. Blepharitis market is also expected to grow due to increasing number of drugs in the pipeline.

Get a Request Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1761

For instance, ISV-305 sponsored by InSite Vision is in phase 3 clinical trials, ISV-305 treats patients with early symptoms of blepharitis. Furthermore, new product launches and mergers and acquisitions over the recent past also contributes to market growth. For instance, in 2015, BlephEx, a Franklin-based company launched Rysurg. It is used to clean eyelids and also maintains hygiene.

According to a study conducted by American Academy of Ophthalmology in 2015 around 50% of ophthalmic patients suffer from symptoms of blepharitis and dry eyes. Constant use of this device helps prevent recurrence of blephairis and the treatment is pain-free. In 2013, Shire Plc, purchased Californian Ophthalmic Company SARcode Bioscience to add new drug lifitegrast to Shire’s specialist drug portfolio. Lifitegrast was approved by the FDA for the treatment of signs and symptoms of dry eye and blepharitis in 2016.

According to a survey conducted in the U.S., by Population Reference Bureau in 2016, states that the aging population increased by 24% as compared to 15% in 2014. Europe is expected to witness rapid growth due to new product launches of blepharitis drugs in the region. For instance, in 2017, Scope Ophthalmic launched Moist Heat Mask, a device that helps in the treatment of blepharitis by loosening the oil present in Meibomian glands and allowing it to flow more freely. It helps to soften eye lash debris, prevent the evaporation of natural tear film, restores moisture to the eye and also the surrounding area, as well as improves tear film lipid quality.

In 2015, MiBo Medical Group, a U.K.-based company, launched MibO Thermoflo. This device helps in the treatment of blepharitis and dry eyes and is required to be gently massaged on the margins of the eyelids for a minimum of 12 minutes. In 2015, MiBo Medical Group launched Lid Pro, a device that is used to treat anterior Blepharitis. The region of Asia Pacific is expected to witness significant growth due to increasing prevalence of blepharitis. According to a study conducted by Journal of Clinical and Experimental Ophthalmology in 2016, signs and symptoms of blepharitis increased by 32% among the geriatric population as compared to 2014.

Request for Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/1761

Key players operating in the Blepharitis treatment market include Scope Ophthalmic Ltd, NovaBay Pharmaceuticals Inc, Thea Pharmaceuticals Ltd, Perrigo Laboratories, InSite Vision Incorporated, Merck & Co, and Novartis AG

Blepharitis Treatment Market Taxonomy:-

The global Blepharitis treatment market is segmented based on disease type, treatment type, distribution channel, and region.

By Disease Type:-

Posterior Blepharitis
Anterior Blepharitis
Mixed Blepharitis
By Treatment Type:-

Antibiotic Therapy
Topical Corticosteroids
Topical Antibodies
Oral Antibodies
Ointments
Eye Cleansers
Others
By Distribution Channel:-

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:-

North America
Europe
Latin America
Asia-Pacific
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.